Global UrethralStricture Treatment Market, by Type (Posterior Urethral Stricture andAnterior Urethral Stricture), by Treatment (Urethral Dilation, Direct VisionInternal Urethrotomy (DVIU), Urethroplasty (Anastomotic Urethroplasty andSubstitution Urethroplasty), and Others), by Disease Indication (Iatrogenic,Idiopathic, Infection-induced, Trauma, and Others), by End User (Hospitals,Ambulatory Surgical Center, and Others), and by Region (North America, LatinAmerica, Europe, Asia Pacific, Middle East, and Africa) is estimated to bevalued at US$ 1,326.0 million in 2019, and is expected to exhibit a CAGR of6.0%, during the forecast period (2019-2027), as highlighted in a new reportpublished by Coherent Market Insights.
Technological advancement forimproving success rate and to lower pain with quick recovery are factorsboosting growth of the market. Tissue engineering is one of the current trendsin the treatment of urethral stricture. MukoCell, a graft for urethroplasty,developed by UroTiss Europe GmbH is proving as breakthrough option in tissueengineering. Increasing number of anterior urethral stricture cases is expectedto be a major factor for growth of the market. According to the National Centerfor Biotechnology Information (NCBI), in 2019, around 1,242 bulbar urethralstrictures were treated with 14 different surgical techniques in Italy. Theoverall success rate ranged from 87.5% to 14.3% using different techniques.Anterior urethral stricture are the most commonly occurring stricture and arecaused due to infection or trauma leading to spongiofibrosis. Anterior urethralstricture mostly occurs in the bulbar urethra which represents around 46.9% ofstrictures, penile shares around 30.5%, penile & bulbar may represent 9.9%,and panurethral is least representing 4.9% strictures.
* The sample copy includes:Report Summary, Table of Contents, Segmentation, Competitive Landscape, ReportStructure, Methodology.
Request a sample copyof this report: https://www.coherentmarketinsights.com/insight/request-sample/2381
Browse 45 Market Data Tables and37 Figures spread through 195 Pages and in-depth TOC on 'Global UrethralStricture Treatment Market, by Type (Posterior Urethral Stricture and AnteriorUrethral Stricture), by Treatment (Urethral Dilation, Direct Vision InternalUrethrotomy (DVIU), Urethroplasty (Anastomotic Urethroplasty and SubstitutionUrethroplasty), and Others), by Disease Indication (Iatrogenic, Idiopathic,Infection-induced, Trauma, and Others), by End User (Hospitals, AmbulatorySurgical Center, and Others), and by Region (North America, Latin America,Europe, Asia Pacific, Middle East, and Africa) - Global Forecast to 2027'
Urethroplasty is a technique usedfor reconstruction of the infected section of the urethra. According to theColumbia University Irving Medical Center Department of Urology, Urethroplastyis considered as the ‘gold standard’ for urethral reconstruction, as it offerslong-lasting results. Urethroplasty has transformed medical procedures byoffering benefits such as lower chances of relapse of urethral stricture,reduced threat of inflammation in the area, and improved quality of life.According to the British Association of Urological Surgeons (BAUS) Limited,urethroplasty is the most preferred procedure globally, with a success rate ofover 85.0%.
Moreover, adoption of inorganicstrategies such as collaborations and acquisitions by major players in theurethral stricture treatment market are expected to drive growth of the market.For instance, in December 2018, Amecath Medical Technologies announced theexpansion of its business in Paraguay in collaboration with InfinityInternational, a healthcare service provider based in Latin America to cater tothe growing demand for urological disease treatment.
Browse ResearchReport: https://www.coherentmarketinsights.com/market-insight/urethral-stricture-treatment-market-2381
Furthermore, increasing productapprovals by regulatory authorities is also expected to drive the marketgrowth. For instance, in April 2018, Urotronic, Inc. received the U.S. Food andDrug Administration approval for Optilume drug-coated balloon (DCB) catheterfor the treatment of male patients suffering from urethral strictures.
Key Takeaways of the Global UrethralStricture Treatment Market:
The global urethral stricturetreatment market is expected to exhibit a CAGR of 6.0% during the forecastperiod (2019-2027), owing to increasing product launches. For instance, inFebruary 2017, Cook Medical, a subsidiary of Cook Group, added two new sets ofureteral stents for percutaneous urinary drainage in its Universa productportfolio. The Universa brand of urinary drainage products also includesureteral stents and Foley catheters that are available in multiple sizes andconfigurations to meet patient needs and physician preference.
Increasing clinical trials by keyplayers are also estimated to drive the growth of the global urethral stricturetreatment market over the forecast period. For instance, in June 2018,Urotronic Inc. collaborated with ClinLogix. LLC to initiate a clinical trialstudy to establish the safety and effectiveness of the Optilume Stricture DrugCoated Balloon (DCB). The study is expected to complete in November 2024.
Major players operating in theglobal urethral stricture treatment market include Becton, Dickinson andCompany, Amecath, Zhejiang Chuangxiang, Medical Technology Co., Ltd, AlliumLtd., SURGIMEDIK, Cook Group, Taewoong Medical Co., Ltd., TeleflexIncorporated, B. Braun Melsungen AG, Coloplast A/S, Boston ScientificCorporation, and Pnn Medical A/S.
Buy-Now this researchreport: https://www.coherentmarketinsights.com/insight/buy-now/2381
AboutCoherent Market Insights:
CoherentMarket Insights is a prominent market research and consulting firm offeringaction-ready syndicated research reports, custom market analysis, consultingservices, and competitive analysis through various recommendations related toemerging market trends, technologies, and potential absolute dollaropportunity.
ContactUs:
mailto:sales@coherentmarketinsights.com
U.S.Office:
Name: Mr. Shah
CoherentMarket Insights 1001 4th Ave,
# 3200Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
